“The premise of Lantern is to use the most current advances in machine learning, artificial intelligence, and genomics to help rescue and develop cancer drugs faster and cheaper and with lower risk so we can get them to patients in a more personalized manner,” says Panna Sharma, CEO of Lantern Pharma.

Sharma was drawn to the premise of Lantern primarily because it just makes sense, given the tremendous amount of molecular and genomic data now available on hundreds of different types of cancers. The technology being employed by Lantern Pharma has the ability to identify which drugs have worked for some people in the past, why they worked, and how to predict which patients may benefit from them in the future.

As a result, the Lantern Pharma technology is rescuing certain cancer drugs which have the potential to work extremely well for some patients, despite not making it to the market for being deemed not effective enough. They’re also using this technology to drive the development of new drugs. On today’s episode, you will discover:

• How many cancer drugs are already built in to the Lantern Pharma model
• How many gene expression profiles there are within a given tumor
• The importance of understanding a tumor’s response to a given drug

Interested in learning more? Tune in and visit https://www.lanternpharma.com/.

Podcast: Play in new window | Download | Embed